Treatment failure is still a problem for many individuals with HIV. In Europe alone, over 10,000 individuals with HIV are classed as "heavily treatment experienced"1 – but what does this really mean?

Professor Chloe Orkin and her colleagues Pedro Cahn, Antonella Castagna, Brinda Emu, Richard Harrigan, Dan Kuritzkes, Mark Nelson and Jonathan Schapiro met in December 2020 and again in 2021. Their discussions will be submitted for publication as a manuscript to identify the unmet needs of individuals with HIV who are in need of further treatment options, broaden the definition of heavily treatment experienced people, and clarify the use of newer agents, with an emphasis on the utilization of entry inhibitors in this population.

Program learning objectives

Identify individuals with HIV who have limited treatment options and describe their needs

Describe the different mechanisms of action of existing and novel entry inhibitors

Understand the impact different HIV entry inhibitors have on immune recovery

Describe and manage toxicities associated with HIV entry inhibitors

Register for free today to open the door on entry inhibitors and learn more about their important role in the treatment of people living with HIV.

  1. Pelchen-Matthews A, et al. Poster TUPEB222. 10th IAS Conference on HIV Science; July 21-24; Mexico City, Mexico 2019.